The approximately $30 million acquisition of CellRight Technologies, along with its spinal surgery and orthopedic portfolio, was completed by England-based Tissue Regenix. The transaction helps position Tissue Regenix for the release early next year of its OrthoPure HT decellularized human tendon in the US to address repair of cruciate ligaments, the company said.
$30M deal to acquire CellRight completed by Tissue Regenix
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.